Oak Hill Bio merges with RA Capital SPAC; InnoCare's TYK2 drug hits in Phase 3
💵 Oak Hill Bio’s SPAC merger: The Angelman syndrome biotech will merge with RA Capital’s blank-check company, called Research Alliance Corporation III, and get about ...
July 28, 2026 11:17 AM EDT News Briefing Oak Hill Bio merges with RA Capital SPAC; InnoCare's TYK2 drug hits in Phase 3 ENDPOINTS 💵 Oak Hill Bio’s SPAC merger: The Angelman syndrome biotech will merge with RA Capital’s blank-check company, called … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that